PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $137.00 (from $130.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




